GVHD disease etc etc., funding Berger's lifestyle, etc. etc., :( They were a product of the human genome class of companies. They went from genomics to concentrating on oncology small molecule drugs when the NASDAQ bubble imploded.
Ironically, AP1903 is being developed by Bellicum now. It has show some pretty damn (early) results in GVHD and prostate cancer. Ariad has a equity stake in the company.
News 
Market Data 
Discover 
AI
